title: Multitargeted approach using antisense oligonucleotides for the treatment of asthma.
abstract: Asthma is characterized by inflammation and hyperresponsiveness related to the accumulation of inflammatory cells, particularly eosinophils, within the airways. We tested the hypothesis that a multitargeted approach is better than a single-targeted approach in a rat model of asthma. We simultaneously delivered oligonucleotides (ODNs) targeting the chemokine receptor CCR3 and the common beta chain subunit of the receptors for IL-3, IL-5, and GM-CSF at the time of ovalbumin challenge in sensitized Brown Norway rats. Fewer eosinophils were detected in bronchoalveolar lavage (BAL) of rats treated with both ODNs as compared to each ODN alone. Moreover, airway responsiveness to LTD(4) was significantly decreased at lower doses in the 2 ODN-treated groups compared to a single ODN. As ODN therapy has raised concerns of toxicity we therefore examined ODNs prepared with modified DNA bases, specifically 2'amino, 2'deoxyadenosine (DAP) in place of adenosine. In vivo, administration of individual DAP-ODN was efficacious in inhibiting airway hyperresponsiveness, whereas delivery of 2 DAP-ODNs (targeting CCR3 and common beta chain) reduced the influx not only of eosinophils but also lymphocytes and macrophages in the lungs of rats as compared to the unmodified ODNs. Blocking multiple inflammatory pathways simultaneously is more effective in preventing eosinophilia and airway hyperresponsiveness than inhibiting either pathway alone. The challenges associated with the development of a product containing two oligonucleotides in humans are discussed.
authors.affiliation: CHUM Research Center, Notre-Dame Hospital, Montreal, Quebec, Canada.
authors.forename: Z
authors.initials: Z
authors.lastname: Allakhverdi
authors.forename: M
authors.initials: M
authors.lastname: Allam
authors.forename: A
authors.initials: A
authors.lastname: Guimond
authors.forename: N
authors.initials: N
authors.lastname: Ferrari
authors.forename: K
authors.initials: K
authors.lastname: Zemzoumi
authors.forename: R
authors.initials: R
authors.lastname: Séguin
authors.forename: L
authors.initials: L
authors.lastname: Paquet
authors.forename: P M
authors.initials: PM
authors.lastname: Renzi
mesh_terms: D000818:Animals; D001249:Asthma / Q000188:drug therapy*; D016535:Bronchial Hyperreactivity / Q000188:drug therapy; D004195:Disease Models, Animal; D004802:Eosinophilia / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D008252:Macaca fascicularis; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D051381:Rats; D054397:Receptors, CCR3; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors; D016187:Receptors, Granulocyte-Macrophage Colony-Stimulating Factor / Q000037:antagonists & inhibitors; D016185:Receptors, Interleukin-3 / Q000037:antagonists & inhibitors; D053649:Receptors, Interleukin-5 / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: C515350:CCR3 protein, human; C515352:Ccr3 protein, rat; D016376:Oligonucleotides, Antisense; D054397:Receptors, CCR3; D019707:Receptors, Chemokine; D016187:Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; D016185:Receptors, Interleukin-3; D053649:Receptors, Interleukin-5